| 1.725 -0.175 (-9.21%) | 04-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.47 | 1-year : | 18.07 |
| Resists | First : | 13.25 | Second : | 15.47 |
| Pivot price | 7.08  |
|||
| Supports | First : | 6.35 | Second : | 2.09 |
| MAs | MA(5) : | 12.69 |
MA(20) : | 5.89 |
| MA(100) : | 4.35 |
MA(250) : | 9.67 |
|
| MACD | MACD : | 2.7 |
Signal : | 1.7 |
| %K %D | K(14,3) : | 97.3 |
D(3) : | 97.7 |
| RSI | RSI(14): 86.8 |
|||
| 52-week | High : | 28.5 | Low : | 1.1 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EIGR ] has closed below upper band by 20.1%. Bollinger Bands are 480.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 13.12 - 13.19 | 13.19 - 13.23 |
| Low: | 12.05 - 12.13 | 12.13 - 12.19 |
| Close: | 12.97 - 13.11 | 13.11 - 13.19 |
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Mon, 01 Jul 2024
Will Eiger BioPharmaceuticals Continue to Surge Higher? - Yahoo Movies UK
Sun, 30 Jun 2024
Eiger BioPharmaceuticals to Present at the Jefferies Global Healthcare Conference - Quantisnow
Sat, 29 Jun 2024
Eiger BioPharmaceuticals Strengthens Management Team with New Appointments - Quantisnow
Thu, 27 Jun 2024
Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Lifestyle Singapore
Wed, 03 Apr 2024
Eiger BioPharmaceuticals: Bankruptcy, Delisting, and Board Resignation - TipRanks.com - TipRanks
Mon, 01 Apr 2024
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 11.8 (%) |
| Held by Institutions | 43.8 (%) |
| Shares Short | 34 (K) |
| Shares Short P.Month | 42 (K) |
| EPS | -58.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.09 |
| Profit Margin | 0 % |
| Operating Margin | -527.6 % |
| Return on Assets (ttm) | -52.5 % |
| Return on Equity (ttm) | -226 % |
| Qtrly Rev. Growth | -20.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 9.91 |
| EBITDA (p.s.) | -56.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -83 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -0.22 |
| PEG Ratio | 0 |
| Price to Book value | -11.72 |
| Price to Sales | 1.27 |
| Price to Cash Flow | -0.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|